Trial Profile
A retrospective study analysing safety and efficacy of Rivaroxaban in patients with non-valvular atrial fibrillation and severe renal impairment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Sep 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2016 New trial record